JNJ-26146900

JNJ-26146900
Clinical data
Other names	JNJ26146900
Drug class	Selective androgen receptor modulator
Identifiers
	IUPAC name 2-[(2R)-1-ethylsulfonyl-2-hydroxypropan-2-yl]-6-(trifluoromethyl)-1H-indole-5-carbonitrile;
CAS Number	868691-50-3;
PubChem CID	11602942;
ChemSpider	9777698;
UNII	3397AFW49K;
ChEMBL	ChEMBL395886;
Chemical and physical data
Formula	C15H15F3N2O3S
Molar mass	360.35 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCS(=O)(=O)C[C@@](C)(C1=CC2=CC(=C(C=C2N1)C(F)(F)F)C#N)O;
	InChI InChI=1S/C15H15F3N2O3S/c1-3-24(22,23)8-14(2,21)13-5-9-4-10(7-19)11(15(16,17)18)6-12(9)20-13/h4-6,20-21H,3,8H2,1-2H3/t14-/m0/s1; Key:UJGGNFGSHPHGNE-AWEZNQCLSA-N;

JNJ-26146900 is a selective androgen receptor modulator (SARM) which was developed by Johnson & Johnson for the potential treatment of prostate cancer but was never marketed.^[1]^[2]^[3]^[4]^[5]^[6]

^ "Delving into the Latest Updates on JNJ-26146900 with Synapse". Synapse. 12 October 2024. Retrieved 22 October 2024.
^ Mohler ML, Bohl CE, Narayanan R, He Y, Hwang DJ, Dalton JT, et al. (20 August 2008), Nonsteroidal Tissue-Selective Androgen Receptor Modulators, Wiley, pp. 249–304, doi:10.1002/9783527623297.ch8, ISBN 978-3-527-31872-8, ISSN 1865-0562, Several articles characterizing compounds of Template 3 (Figure 8.13), the indoles were recently published with only JNJ26146900 (78) demonstrating tissue-selective activity [178]. JNJ26146900 (78) retains LA weight, but reduces prostate weight in intact animals, and partially offsets castration-induced losses in BMD and LBM. JNJ26146900 blocked testosterone-induced prostate cancer growth and demonstrated favorable activity in a prostate cancer xenograft model using CWR22-LD1 prostate cancer cells (Figure 8.13, top right).
^ Bai C, Flores O, Schmidt A (May 2007). "Opportunities for development of novel therapies targeting steroid hormone receptors". Expert Opinion on Drug Discovery. 2 (5): 725–737. doi:10.1517/17460441.2.5.725. PMID 23488961. Furthermore, SARMs such as JNJ-26146900 that have been shown to antagonize the growth of prostate tumors in animal models while maintaining anabolic effects on bone and muscle may provide an alternative to current therapies in the management of PCa.
^ Fan P, Jordan VC (24 June 2013). "An Emerging Principle: Selective Nuclear Receptor Modulators". Estrogen Action, Selective Estrogen Receptor Modulators and Women's Health. Imperial College Press. pp. 431–456. doi:10.1142/9781848169586_0016. ISBN 978-1-84816-957-9. The recently developed compound JNJ-26146900 (Johnson & Johnson Pharmaceutical Research and Development) acts as a pure androgen antagonist of prostate cancer while maintaining anabolic effects on bone and muscle in rats.12 Its profile makes it a strong candidate for consideration as the future antiandrogen SARMs in the treatment of advanced prostate cancer.
^ Tabbal M, Fuleihan EH (2010). "Future Therapies". Osteoporosis in Men. Elsevier. pp. 713–732. doi:10.1016/b978-0-12-374602-3.00057-2. ISBN 978-0-12-374602-3. In an intact animal model, an indole SARM, JNJ-26146900, was shown to reduce prostate weight, similarly to the androgen antagonist bicalutamide and, in a mouse xenograft model of prostate cancer, it reduced testosterone-induced prostate growth. The compound also prevented orchidectomy-induced loss of muscle and bone mass and improved material properties of bone as assessed by BV, trabecular connectivity and number [68].
^ Allan G, Lai MT, Sbriscia T, Linton O, Haynes-Johnson D, Bhattacharjee S, et al. (January 2007). "A selective androgen receptor modulator that reduces prostate tumor size and prevents orchidectomy-induced bone loss in rats". The Journal of Steroid Biochemistry and Molecular Biology. 103 (1): 76–83. doi:10.1016/j.jsbmb.2006.07.006. PMID 17049844.

[Synapse-1] "Delving into the Latest Updates on JNJ-26146900 with Synapse". Synapse. 12 October 2024. Retrieved 22 October 2024.

[MohlerBohlNarayanan2008-2] Mohler ML, Bohl CE, Narayanan R, He Y, Hwang DJ, Dalton JT, et al. (20 August 2008), Nonsteroidal Tissue-Selective Androgen Receptor Modulators, Wiley, pp. 249–304, doi:10.1002/9783527623297.ch8, ISBN 978-3-527-31872-8, ISSN 1865-0562, Several articles characterizing compounds of Template 3 (Figure 8.13), the indoles were recently published with only JNJ26146900 (78) demonstrating tissue-selective activity [178]. JNJ26146900 (78) retains LA weight, but reduces prostate weight in intact animals, and partially offsets castration-induced losses in BMD and LBM. JNJ26146900 blocked testosterone-induced prostate cancer growth and demonstrated favorable activity in a prostate cancer xenograft model using CWR22-LD1 prostate cancer cells (Figure 8.13, top right).

[BaiFloresSchmidt2007-3] Bai C, Flores O, Schmidt A (May 2007). "Opportunities for development of novel therapies targeting steroid hormone receptors". Expert Opinion on Drug Discovery. 2 (5): 725–737. doi:10.1517/17460441.2.5.725. PMID 23488961. Furthermore, SARMs such as JNJ-26146900 that have been shown to antagonize the growth of prostate tumors in animal models while maintaining anabolic effects on bone and muscle may provide an alternative to current therapies in the management of PCa.

[FanJordan2013-4] Fan P, Jordan VC (24 June 2013). "An Emerging Principle: Selective Nuclear Receptor Modulators". Estrogen Action, Selective Estrogen Receptor Modulators and Women's Health. Imperial College Press. pp. 431–456. doi:10.1142/9781848169586_0016. ISBN 978-1-84816-957-9. The recently developed compound JNJ-26146900 (Johnson & Johnson Pharmaceutical Research and Development) acts as a pure androgen antagonist of prostate cancer while maintaining anabolic effects on bone and muscle in rats.12 Its profile makes it a strong candidate for consideration as the future antiandrogen SARMs in the treatment of advanced prostate cancer.

[TabbalFuleihan2010-5] Tabbal M, Fuleihan EH (2010). "Future Therapies". Osteoporosis in Men. Elsevier. pp. 713–732. doi:10.1016/b978-0-12-374602-3.00057-2. ISBN 978-0-12-374602-3. In an intact animal model, an indole SARM, JNJ-26146900, was shown to reduce prostate weight, similarly to the androgen antagonist bicalutamide and, in a mouse xenograft model of prostate cancer, it reduced testosterone-induced prostate growth. The compound also prevented orchidectomy-induced loss of muscle and bone mass and improved material properties of bone as assessed by BV, trabecular connectivity and number [68].

[AllanLaiSbriscia2007-6] Allan G, Lai MT, Sbriscia T, Linton O, Haynes-Johnson D, Bhattacharjee S, et al. (January 2007). "A selective androgen receptor modulator that reduces prostate tumor size and prevents orchidectomy-induced bone loss in rats". The Journal of Steroid Biochemistry and Molecular Biology. 103 (1): 76–83. doi:10.1016/j.jsbmb.2006.07.006. PMID 17049844.

[1]

[2]

[3]

[4]

[5]

[6]